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Translational Relevance
Numerous studies have demonstrated that constitutive activation of nuclear factor-κB (NF-κB) signaling plays vital roles in the development and progression of esophageal squamous cell carcinoma (ESCC). Functioning as physical platform, lipid rafts have been reported to be essential for NF-κB signaling transduction via inducing signaling molecules in close proximity. Herein, we found that downregulation of miR-138 enhanced, whereas upregulation of miR-138 reduced, the aggressive phenotype of ESCC cells both in vitro and in vivo. Silencing of miR-138 promoted K63-linked polyubiquitination of the NF-κB signaling intermediaries TRAF2 and RIP1, and sustained NF-κB activation. Furthermore, downregulation of miR-138 induced lipid raft formation via upregulation of multiple constitutive components of lipid rafts, including FLOT1, FLOT2 and caveolin-1. Therefore, our study highlights an important tumor-suppressive role for miR-138 in ESCC progression, ; miR-138 may possibly be employed as a novel prognostic marker and/or as an effective therapeutic target for ESCC.
Introduction
Esophageal squamous cell carcinoma (ESCC), one of the most aggressive malignancies of the gastrointestinal tract, is the sixth most common cause of cancer-related deaths worldwide (1, 2) . Numerous studies have revealed that constitutive activation of nuclear factor-κB (NF-κB) signaling plays vital roles in the development and progression of ESCC, and blockade of the NF-κB pathway can inhibit ESCC proliferation, sensitize ESCC to chemotherapeutic drugs, and suppress angiogenesis and metastasis in ESCC (3, 4) .
However, the precise molecular mechanisms which regulate the NF-κB pathway in ESCC are still not completely understood.
Lipid rafts are defined as small (10-200nm) , highly dynamic liquid-ordered domains that are enriched with cholesterol and glycosphingolipids, and are physically characterized by their insolubility in Triton X-100 at 4°C (5, 6) . Functioning as a physical platform, lipid rafts have been reported to be essential for NF-κB signaling transduction via inducing signaling molecules in close proximity (7) (8) (9) (10) (11) . In response to tumor necrosis factor-α (TNF-α), TNF-α receptor (TNFR) translocates to lipid rafts and forms a signaling complex through association with the adaptor proteins, TRADD, TRAF2 and RIP1. Meanwhile, TRAF2 and RIP1 in lipid rafts are rapidly K63-polyubiquitylated, which facilitates the recruitment and activation of TAK1 and IKK complexes, resulting in phosphorylation and ubiquitin-proteasomal degradation of IκBs, and consequently leading to NF-κB activation.
It is of note that interfering with lipid raft composition not only inhibits TNF-α-mediated NF-κB activation, but also provokes TNF-α-induced apoptosis, which indicates that lipid raft formation is associated with the outcomes of TNF-α treatment (7) . Lipid rafts have also been reported to be essential for NF-κB activation induced by a diverse set of stimuli, such as interleukin-1 beta (IL-1β), CD40L and lipopolysaccharides (LPS) (8, 9, 12 these findings indicate that lipid rafts play important roles in the activation of proximal NF-κB signaling.
Two types of lipid rafts have been proposed, namely caveolar raft/caveolae and non-caveolar lipid rafts (5, 6) . As an indispensable prerequisite for non-caveolar raft formation, flotillins/reggies, including flotillin-1 (FLOT1 or Reggie-2) and flotillin-2 (FLOT2 or Reggie-1), have been reported to be overexpressed in various types of cancer, and are associated with the development and progression of cancer (13) (14) (15) (16) (17) (18) . On the other hand, caveolin-1, an essential protein that exerts a scaffolding function in caveolar raft/caveolae formation, is also found to be elevated in multiple types of human cancer, and overexpression of caveolin-1 results in tumor progression and metastasis (19) (20) (21) .
In this study, we reported that miR-138 is downregulated in ESCC cells and clinical ESCC tumors. We found that silencing miR-138 induces lipid raft formation via upregulation of multiple constitutive components of lipid rafts, including FLOT1, FLOT2 and caveolin-1, leading to NF-κB activation and the promotion of aggressiveness in ESCC. These results demonstrate that miR-138 functions as a tumor-suppressive miRNA in ESCC through inhibition of proximal NF-κB signaling.
Research. Vectors, retroviral infection and transfection. The human miR-138 gene was PCR-amplified from genomic DNA and cloned into a pMSCV-puro retroviral vector. The miR-138 anti-sense was cloned into miRZip plasmid purchased from System Biosciences (San Francisco, CA) and used according to previous report (24) . The 3'-UTR regions of human FLOT1, FLOT2 and caveolin-1, generated by PCR amplification from genomic DNA isolated from NEEC, were cloned into the pGL3-luciferase reporter plasmid (Promega, Madison, WI). The point mutations in the tentative miR-138-binding seed regions were created using the Strategene QuickChange Mutagenesis Kit (Stratagene, La Jolla, CA). Luciferase and renilla signals were measured using the Dual Luciferase Reporter Assay Kit (Promega) according to a protocol provided by the manufacturer.
Lipid Raft Isolation. Lipid rafts were isolated by sucrose density gradient centrifugation essentially as described (25) . In brief, subconfluent cells from two 15cm culture dishes were lysed on ice for 20 min in 1ml of MNX buffer (1% Triton X-100 in 25mM MES, 150mM NaCl [pH 6.5], 1mM Na 3 VO 4 ) supplemented with 10μg/ml benzamidine, 2μg/ml antipain, and 1μg/ml leupeptin, and homogenized with a loose-fitting glass dounce homogenizer (Polylabo, Illkirch, France). The homogenates were mixed with equal amount 85% sucrose made with MNX buffer and placed on the bottom of a centrifuge tube. The samples were then overlaid with 6 ml of 35% sucrose and 3ml of 5% sucrose and centrifuged at 200,000 g in a Hitachi CP80WX centrifuge (Hitachi, Tokyo, Japan) for 20h at 4°C. One milliliter fractions were collected from the top of the gradient and analyzed by Western blotting. The pellet present at the bottom of the gradient was sonicated in 1 ml of MNX. 
Statistical analysis. Statistical tests for data analysis included

Results
Reduced expression of miR-138 correlates with ESCC progression and poor prognosis
By analyzing published miRNA expression profiles obtained from 153 primary ESCC tissues and 104 normal esophageal tissues (NCBI/GEO/GSE6188), miR-138 was identified to be significantly downregulated in ESCC tissues compared to normal tissues (Fig.1A) .
Furthermore, real-time PCR analysis revealed that miR-138 was downregulated in all 9 tested ESCC cell lines compared to 2 normal esophageal epithelial cells (NEECs), and in 20 ESCC samples compared to the matched adjacent non-tumor tissues (Figs.1B-1C) .
Collectively, these results indicate that miR-138 expression is reduced in ESCC.
To evaluate whether downregulation of miR-138 correlates with clinical ESCC progression, we examined miR-138 expression in 205 archived human ESCC specimens.
Statistical analyses revealed that miR-138 expression inversely correlated with the clinical stage (P < 0.001), TNM classification (P <0.001) and histological differentiation (P = 0.024) in patients with ESCC ( Supplementary Fig.1 and Supplementary Table 2 ). Importantly, patients with lower miR-138 expression had a shorter survival time, whereas patients with higher miR-138 expression had a longer survival time (P < 0.001; Fig.1D ). Univariate and multivariate analyses revealed that clinical stage and miR-138 expression were each recognized as independent prognostic factors in ESCC (Supplementary Table 3 ). Taken together, these results suggest a possible link between reduced expression of miR-138 and the progression of human ESCC.
Downregulation of miR-138 promotes the aggressiveness of ESCC cells in vitro
To investigate the biological role of miR-138 downregulation in ESCC progression, we Figs.3A-3F ). These results suggest that downregulation of miR-138 promotes ESCC aggressiveness.
Downregulation of miR-138 contributes to ESCC progression in vivo
The biological effect of miR-138 reduction on ESCC progression was further examined using an in vivo tumor model. As shown in Figs (Fig.2D) . Taken together, our results demonstrate that miR-138 downregulation contributes to ESCC progression in vivo.
miR-138 downregulation sustains NF-κB activity
Notably, we observed that the number of F4/80-positive cells, the infiltrating macrophages, was significantly increased in miR-138-downregulated tumors and reduced in miR-138-overexpressing tumors compared with the respective control tumors (Fig.2D), suggesting that miR-138 might play a role in the regulation of NF-κB signaling. Indeed, downregulation of miR-138 significantly enhanced, whereas overexpression of miR-138
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reduced, NF-κB luciferase activity and the expression of numerous NF-κB downstream genes in ESCC cells (Figs.3A-3B) . Furthermore, EMSA assay revealed that the NF-κB DNA binding activity was drastically increased in miR-138-silenced cells and decreased in miR-138-transduced cells ( Supplementary Fig.4) . Importantly, overexpressing IκBα-mut drastically reduced the size of the tumors formed by miR-138-silenced cells ( Supplementary   Fig.5 ), suggesting that NF-κB signaling plays a critical role in silencing miR-138-induced ESCC aggressiveness.
As expected, the expression levels of phosphorylated-IKK-β and-IκBα were significantly increased in miR-138-silenced ESCC cells, but decreased in miR-138-transduced cells (Fig.3C) . Strikingly, we observed that downregulation of miR-138 significantly prolonged, whereas overexpression of miR-138 restrained, the decreased IκBα level induced by TNF-α treatment ( Supplementary Fig.6 ). Comparable results were also obtained using an in vitro kinase assay, as chronic activation of the endogenous IKK kinase complex was persistent in miR-138-silenced cells but rapidly decreased in miR-138-transduced cells (Fig.3D) . These results suggest that silencing miR-138 sustains NF-κB activation in ESCC cells.
Lipid rafts contribute to miR-138 downregulation-mediated NF-κB activation
The levels of K63-polyubiqutination of TRAF2 and RIP1 were dramatically increased in miR-138-silenced cells and decreased in miR-138-transduced cells compared with the respective control cells (Fig.4A) , indicating that miR-138 is involved in modulating the ubiquitination of NF-κB signaling. Interestingly, the expression levels of TNFR, TRAF2, RIP1 and IKK-β were lower in lipid rafts isolated from control cells compared to miR-138-silenced ESCC cells, but higher than the levels in lipid rafts isolated from miR-138-transduced cells (Fig.4B) revealed that the quantity of ganglioside GM1, a marker of lipid rafts (26) , drastically increased in miR-138-silenced cells and decreased in miR-138-transduced cells compared to the respective vector cells (Fig.4C) , indicating that miR-138 downregulation also induce lipid raft formation. Moreover, disrupting lipid rafts using methyl-β-cyclodextrin (MβCD) significantly inhibited NF-κB activity in miR-138-silenced cells (Fig.4D) , further demonstrating that lipid rafts contribute to silencing miR-138-mediated NF-κB activation.
MiR-138 directly suppresses multiple constitutive components of lipid rafts
Using publicly available algorithms (PITA and TargetScan5.2), we found that FLOT1, FLOT2 and caveolin-1, the constitutive components of lipid rafts (15) (16) (17) (18) (19) (20) (21) (22) (23) , might be potential targets of miR-138 (Fig.5A) . Western blotting analysis revealed that the expression of FLOT1, FLOT2 and caveolin-1 increased in miR-138-silenced cells, but decreased in miR-138-transduced cells (Fig.5B) . Luciferase assay showed that overexpression of miR-138 attenuated, but downregulation of miR-138 elevated, the reporter activities driven by the 3'UTRs of these transcripts. However, dysregulation of miR-138 did not result in the alteration of the reporter activities driven by the mutated 3'-UTRs of these transcripts within miR-138-binding seed regions (Fig.5C) . Moreover, miRNPs immunoprecipitation assay revealed a selective association of miR-138 with FLOT1, FLOT2 and caveolin-1, but not with GAPDH ( Supplementary Fig.7 ), indicating that miR-138 negatively regulates these proteins via directly binding to their 3` UTRs. Additionally, individual silencing of these target genes potently inhibited NF-κB activity in miR-138 silenced cells (Fig.5D and Supplementary Fig.8 ), further demonstrating that FLOT1, FLOT2 and caveolin-1 are functional effectors of miR-138-regulated NF-κB activation.
Clinical relevance of miR-138 downregulation-mediated NF-κB activation in ESCC
Finally, we examined whether miR-138 downregulation-mediated NF-κB activation in ESCC specimens showed that miR-138 levels were inversely correlated with the expression of p-IKK-β, Ki67 and CD31 (P =0.004; P <0.001; P <0.001). In addition, miR-138 expression in 10 freshly collected ESCC samples was also inversely correlated with the mRNA levels of multiple NF-κB downstream targets, including Cyclin D1 (r = -0.754, P =0.012), VEGFC (r = -0.738, P =0.015), Bcl-xL (r = -0.815, P =0.004), MMP9 (r = -0.857, P =0.002), as well as the DNA-binding activity of NF-κB (r = -0.764, P =0.006) (Fig.6C) .
Collectively, our results demonstrate that miR-138 downregulation activates NF-κB signaling through promoting lipid raft formation, resulting in ESCC aggressiveness and poorer clinical outcomes (Fig.6D) . 
Discussion
The key findings of the current study provide new insights into the important role of miR-138 in the inhibition of ESCC progression and NF-κB signaling pathway. We found that miR-138 is downregulated in ESCC, which induces the formation of lipid rafts, resulting in NF-κB activation and promotion of ESCC aggressiveness in vitro and in vivo. These findings uncover a novel mechanism for constitutive NF-κB activation in ESCC and may represent a new target for clinical intervention in human ESCC.
Given their vital role in various signaling transduction pathways, lipid rafts have been demonstrated to contribute to cancer progression through involvement in multiple biological processes, including cell proliferation, apoptosis, angiogenesis and metastasis (10, 11) .
Consistently, FLOT1, FLOT2 and caveolin-1, the markers of lipid rafts, are overexpressed in multiple cancer types and strongly associated with cancer mortality (13) (14) (15) (16) (17) (18) (19) (20) . FLOT1 is upregulated in prostate, breast, infiltrative colorectal and renal cell carcinomas, suggesting that FLOT1 plays an oncogenic role in various cancers (27, 28, (15) (16) (17) . Overexpression of FLOT2 not only transformed non-tumorigenic and non-metastatic melanoma cells into highly tumorigenic and metastatic cells, but also promoted breast cancer progression through the stabilization of the receptor tyrosine kinase ErbB2 (29, 17) . Interestingly, downregulation of caveolin-1 was reported to be important for cell transformation and the induction of breast cancer, while its overexpression contributes to breast cancer cell metastasis, suggesting that caveolin-1 may exert distinct functions during the development and progression of cancer (5, 6, (19) (20) (21) . Similarly to FLOT1, caveolin-1 was reported to be overexpressed in ESCC and positively correlated with patient survival (18, 30) . However Lipid rafts have been demonstrated to play important roles in proximal NF-κB signaling (7) (8) (9) . In response to various stimuli, such as TNF-α, IL-1β, LPS and CD40L, engaged receptors translocate to lipid rafts to form complexes with proximal-signaling intermediates, which induce inflammation and cell survival through IκB kinase (IKK) dependent-activation of NF-κB (7-9). Disruption of lipid rafts or interfering with their composition could block TNF-α-induced translocation of TNFR to lipid rafts and reduce the recruitment of TRAF2 and RIP1 to the engaged receptor (7) . Herein, we found that downregulation of miR-138 in ESCC cells not only promoted the formation of lipid rafts, but also facilitated the recruitment of TNFR and the signaling intermediates, TRAF2 and RIP1, to lipid rafts, suggesting that miR-138 downregulation activates NF-κB at the proximal receptor step. On the other hand, lipid rafts are also required for the ubiquitination of NF-κB signaling intermediaries, which has emerged as an important regulatory mechanism for NF-κB signaling (31, 32) . In agreement with previous reports, silencing miR-138 also promoted the K63-polyubiqutenation levels of TRAF2 and RIP1. Thus, our results suggest that miR-138 plays a regulatory role in receptor proximal signaling-mediated NF-κB activation.
miR-138 has been found to be downregulated in multiple human cancers, and downregulation of miR-138 contributes to cancer cell proliferation and invasion, and inhibits apoptosis via different mechanisms (33-40). However, the expression of miR-138 has also been shown to be upregulated in tumor-initiating glioma stem cells (GSCs) compared to These results further support the notion that a single miRNA may have distinct functions in different cell types (43, 44) .
In summary, given the tumor-suppressive effects of miR-138 and the oncogenic roles of NF-κB signaling in human cancers, our study improves our understanding of ESCC cell biology and tumor progression, but may also allow the development of a novel diagnostic marker and therapeutic strategy for ESCC. Each bar represents the mean ± SD of three independent experiments. * P <0.05. 
